Harvard Bioscience Inc (HBIO) - Total Liabilities
Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has total liabilities worth $67.89 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Harvard Bioscience Inc to track the company's year-over-year net asset growth rate.
Harvard Bioscience Inc - Total Liabilities Trend (1998–2025)
This chart illustrates how Harvard Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Harvard Bioscience Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Harvard Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Harvard Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hamilton Global Opportunities PLC
PA:ALHGO
|
France | €5.46 Million |
|
NSC Groupe SA
PA:ALNSC
|
France | €38.26 Million |
|
Scienjoy Holding Corp
NASDAQ:SJ
|
USA | $172.60 Million |
|
Bowen Acquisition Corp Ordinary Shares
NASDAQ:BOWN
|
USA | $2.61 Million |
|
Bellway PLC
LSE:BWY
|
UK | GBX1.54 Billion |
|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
USA | $82.40 Million |
|
Salee Industry Public Company Limited
BK:SALEE
|
Thailand | ฿269.25 Million |
|
GWR Group Ltd
AU:GWR
|
Australia | AU$7.38 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Harvard Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HBIO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harvard Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harvard Bioscience Inc (1998–2025)
The table below shows the annual total liabilities of Harvard Bioscience Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $66.34 Million | +4.79% |
| 2024-12-31 | $63.30 Million | -1.54% |
| 2023-12-31 | $64.29 Million | -12.10% |
| 2022-12-31 | $73.14 Million | -7.35% |
| 2021-12-31 | $78.94 Million | -0.79% |
| 2020-12-31 | $79.57 Million | -4.33% |
| 2019-12-31 | $83.18 Million | -3.16% |
| 2018-12-31 | $85.89 Million | +201.85% |
| 2017-12-31 | $28.45 Million | -20.00% |
| 2016-12-31 | $35.57 Million | -16.54% |
| 2015-12-31 | $42.62 Million | +5.37% |
| 2014-12-31 | $40.45 Million | -1.29% |
| 2013-12-31 | $40.98 Million | +39.98% |
| 2012-12-31 | $29.27 Million | -5.99% |
| 2011-12-31 | $31.14 Million | -9.88% |
| 2010-12-31 | $34.55 Million | +8.05% |
| 2009-12-31 | $31.97 Million | +119.71% |
| 2008-12-31 | $14.55 Million | -41.12% |
| 2007-12-31 | $24.72 Million | +15.79% |
| 2006-12-31 | $21.34 Million | -9.63% |
| 2005-12-31 | $23.62 Million | -33.51% |
| 2004-12-31 | $35.52 Million | +20.21% |
| 2003-12-31 | $29.55 Million | +53.89% |
| 2002-12-31 | $19.20 Million | +23.49% |
| 2001-12-31 | $15.55 Million | +140.20% |
| 2000-12-31 | $6.47 Million | -48.73% |
| 1999-12-31 | $12.63 Million | +93.00% |
| 1998-12-31 | $6.54 Million | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more